Brown Advisory
ANIP icon

Brown Advisory’s ANI Pharmaceuticals ANIP Stock Holding History

Brown Advisory’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.63M Sell
47,250
-1,174
-2% -$91.6K 0.01% 584
2025
Q4 		$3.82M Buy
48,424
+33,340
+221% +$2.89M 0.01% 579
2025
Q3 		$1.38M Sell
15,084
-1,895
-11% -$155K ﹤0.01% 740
2025
Q2 		$1.11M Buy
16,979
+17
+0.1% +$1.11K ﹤0.01% 786
2025
Q1 		$1.14M Hold
16,962
– – ﹤0.01% 745
2024
Q4 		$938K Hold
16,962
– – ﹤0.01% 818
2024
Q3 		$1.01M Hold
16,962
– – ﹤0.01% 785
2024
Q2 		$1.08M Sell
16,962
-1,490
-8% -$96.7K ﹤0.01% 754
2024
Q1 		$1.28M Hold
18,452
– – ﹤0.01% 723
2023
Q4 		$1.02M Hold
18,452
– – ﹤0.01% 760
2023
Q3 		$1.07M Sell
18,452
-1,600
-8% -$92.3K ﹤0.01% 732
2023
Q2 		$1.08M Sell
20,052
-1,700
-8% -$75.4K ﹤0.01% 735
2023
Q1 		$864K Hold
21,752
– – ﹤0.01% 788
2022
Q4 		$875K Hold
21,752
– – ﹤0.01% 782
2022
Q3 		$699K Hold
21,752
– – ﹤0.01% 784
2022
Q2 		$645K Buy
21,752
+4,118
+23% +$119K ﹤0.01% 790
2022
Q1 		$496K Buy
17,634
+3,333
+23% +$124K ﹤0.01% 862
2021
Q4 		$659K Hold
14,301
– – ﹤0.01% 813
2021
Q3 		$469K Hold
14,301
– – ﹤0.01% 839
2021
Q2 		$501K Hold
14,301
– – ﹤0.01% 842
2021
Q1 		$517K Sell
14,301
-180
-1% -$5.64K ﹤0.01% 838
2020
Q4 		$420K Buy
14,481
+180
+1% +$5.16K ﹤0.01% 814
2020
Q3 		$403K Buy
14,301
+1,991
+16% +$59.3K ﹤0.01% 775
2020
Q2 		$398K Hold
12,310
– – ﹤0.01% 767
2020
Q1 		$502K Hold
12,310
– – ﹤0.01% 691
2019
Q4 		$759K Hold
12,310
– – ﹤0.01% 690
2019
Q3 		$897K Buy
12,310
+1,200
+11% +$89.8K ﹤0.01% 639
2019
Q2 		$913K Hold
11,110
– – ﹤0.01% 649
2019
Q1 		$784K Buy
+11,110
New +$654K ﹤0.01% 864

Other funds holding ANIP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Brown Advisory's ANIP Position: Q1 2026 in Review

Brown Advisory reduced its ANI Pharmaceuticals (ANIP) stake by 2.4% in Q1 2026, selling an estimated $91.6K and leaving 47,250 shares worth $3.63M. The position accounts for 0.01% of the portfolio, ranked #584.

Brown Advisory first reported a position in ANIP in Q1 2019 and has held it in 29 quarters since. The position peaked at $3.82M in Q4 2025. 280 funds tracked by Wall St. Rank hold ANIP as of Q1 2026.

  • Brown Advisory held 47,250 shares of ANI Pharmaceuticals worth $3.63M as of Q1 2026.
  • Brown Advisory sold 1,174 ANI Pharmaceuticals shares in Q1 2026, an estimated $91.6K.
  • ANI Pharmaceuticals made up 0.01% of Brown Advisory's portfolio in Q1 2026, its #584 holding.
  • Brown Advisory first reported a position in ANI Pharmaceuticals in Q1 2019 and has held it in 29 quarters since.
  • Brown Advisory's ANI Pharmaceuticals position peaked at $3.82M in Q4 2025.
  • 280 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2026.

Based on Brown Advisory's 13F filing for Q1 2026, filed 15 May 2026.